ArticlePloS one2015
The Involvement of Immune Semaphorins in the Pathogenesis of Inflammatory Bowel Diseases (IBDs).
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Diverse Roles of Semaphorins on T Cell Activation, Differentiation, Migration, and Effector Functions.Cells · 2026Review
- Participation of Semaphorin Family and Plexins in the Clinical Course of Patients with Inflammatory Bowel Disease.International journal of molecular sciences · 2024Article
- The Involvement of Semaphorins in the Pathogenesis of Skin Diseases.International journal of molecular sciences · 2023Review
- mRNA-engineered mesenchymal stromal cells expressing CXCR2 enhances cell migration and improves recovery in IBD.Molecular therapy. Nucleic acids · 2021Article
- Semaphorin-3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11CBritish journal of pharmacology · 2019Article
- Aggravated mucosal and immune damage in a mouse model of ulcerative colitis with stress.Experimental and therapeutic medicine · 2019Article
- Altered expression of regulatory molecules in the skin of psoriasis.Immunologic research · 2018Article
- Emerging role of semaphorin-3A in autoimmune diseases.Inflammopharmacology · 2018Review
- Neuroimmune semaphorins as costimulatory molecules and beyond.Molecular medicine (Cambridge, Mass.) · 2018Review
- Semaphorin3A: A potential therapeutic tool in immune-mediated diseases.European journal of rheumatology · 2018Review
- Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis.Disease markers · 2018Article
- Guidance Molecules in Vascular Smooth Muscle.Frontiers in physiology · 2018Review
- Semaphorins 4A and 4D in chronic inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- Decreased Expression of Semaphorin3A/Neuropilin-1 Signaling Axis in Apical Periodontitis.BioMed research international · 2017Article
- The role of Sema4A in angiogenesis, immune responses, carcinogenesis, and retinal systems.Cell adhesion & migration · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsImmune semaphorins are a large family of proteins involved in the pathogenesis of inflammatory diseases through the regulation of immune homeostasis and tissue inflammation. We aim to assess the possible involvement of semaphorin3A (sema3A) and 4A (sema4A) in peripheral immune responses and bowel tissue inflammation of patients suffering from Crohn's disease (CD) and ulcerative colitis (UC). PATIENTS AND
methodsTwenty-seven CD patients and 10 UC patients were studied and compared to 10 patients followed for acute diverticulitis (disease control) and 12 healthy individuals. All were evaluated for sema3A expression on T regulatory cells (Tregs), serum levels of sema3A and sema4A, and tissue expression of sema3A and sema4A in bowel biopsies.
resultsThe percentage (%) of T regulatory cells (Tregs) expressing sema3A in patients with active CD (64.5% ± 14.49%) and active UC (49.8% ± 16.45%) was significantly lower when compared to that of healthy controls (88.7% ± 3.6%, p< 0.001 and p< 0.0001, respectively). This expression was seen to be in negative correlation with CD activity. Serum levels of Sema4A were significantly lower in patients with CD and UC when compared to that of controls (5.69 ± 1 .48 ng\ml for CD, 5.26 ± 1.23 ng/ml for UC patients vs 9.74 ± 2.73 ng/ml for normal controls, P<0.001). Sema4A was highly expressed in lymphocytes of the lamina propria of CD and UC patients but absent in patients with diverticulitis or in normal individuals.
conclusionsAltered % of Tregs expressing sema3A in patients with inflammatory bowel diseases (IBD) is partially responsible for their failure in preventing CD4+ effector T cell induced inflammation in IBD in peripheral blood. The increased expression of sema4A in bowel biopsies from CD and UC patients is suggestive of its central role in regulating local tissue inflammation in the bowel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.